Last reviewed · How we verify

ELV/COBI/FTC/TAF — Competitive Intelligence Brief

ELV/COBI/FTC/TAF (ELV/COBI/FTC/TAF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

ELV/COBI/FTC/TAF (ELV/COBI/FTC/TAF) — Fundacion SEIMC-GESIDA. This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication through multiple mechanisms: elvitegravir inhibits integrase, cobicistat boosts drug levels, and emtricitabine and tenofovir alafenamide inhibit reverse transcriptase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ELV/COBI/FTC/TAF TARGET ELV/COBI/FTC/TAF Fundacion SEIMC-GESIDA marketed Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster) HIV integrase, HIV reverse transcriptase
Biktarvy 50/200/25 Tab Biktarvy 50/200/25 Tab Radboud University Medical Center marketed Antiretroviral combination (integrase inhibitor + nucleotide/nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
Bictegravir, emtricitabine, and tenofovir alafenamide Bictegravir, emtricitabine, and tenofovir alafenamide CAN Community Health marketed Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
DTG/ABC/3TC DTG/ABC/3TC Harvard School of Public Health (HSPH) marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
B/FTC/TAF B/FTC/TAF The University of Texas Health Science Center, Houston marketed Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine Raltegravir, tenofovir/emtricitabine University of California, San Francisco marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
dolutegravir/abacavir/lamivudine dolutegravir/abacavir/lamivudine University College Dublin marketed Antiretroviral combination (INSTI + NRTIs) HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster) class)

  1. Fundacion SEIMC-GESIDA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ELV/COBI/FTC/TAF — Competitive Intelligence Brief. https://druglandscape.com/ci/elv-cobi-ftc-taf. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: